Drug name - Complera
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080551 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(6 months from now) | |
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(2 years from now) | |
| CN101056673A | GILEAD SCIENCES INC | 4-[[4-[[4-(2-Cyanovinyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidyl]Amino] Benzonitrile Hydrochloride |
Jun, 2015
(7 years ago) | |
| CN101816658A | GILEAD SCIENCES INC | Pyramine Derivatives For Inhibiting Hiv |
Aug, 2022
(a month ago) | |
| CN101816658B | GILEAD SCIENCES INC | Hiv Inhibiting Pyrimidines Derivatives |
Aug, 2022
(a month ago) | |
| CN1541215A | GILEAD SCIENCES INC | Hiv Inhibiting Pyrimidine Derivatives |
Aug, 2022
(a month ago) | |
| CN100509801C | GILEAD SCIENCES INC | Hiv Inhibiting Pyrimidines Derivatives |
Aug, 2022
(a month ago) | |
| CN101060844B | GILEAD SCIENCES INC | Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors |
Sep, 2024
(1 year, 11 months from now) | |
| CN101068597B | GILEAD SCIENCES INC | 4 - ((4 - ((4 - (2) -2, 6 -) Dimethylphenyl Amido) -2 - Pyrimidyl) Amido) Benzonitrile |
Sep, 2024
(1 year, 11 months from now) | |
| CN101068597A | GILEAD SCIENCES INC | Fumaric Acid Salt Of 4-((4-((4-(2-Cyanovinyl)-2, 6-) Dimethylphenyl Amido)-2- Pyrimidyl) Amido) Benzonitrile |
Sep, 2024
(1 year, 11 months from now) | |
| CN101060844A | GILEAD SCIENCES INC | Composition Of Rt Inhibitor And Nnrti Containing Pyrimidine |
Sep, 2024
(1 year, 11 months from now) | |
| IN200400265P1 | GILEAD SCIENCES INC | Hiv Inhibiting Pyrimidines Derivatives |
Aug, 2022
(a month ago) | |
| IN222987B | GILEAD SCIENCES INC | A Pyrimidine Compound Of Formula (I) |
Aug, 2022
(a month ago) | |
| EP1663240A1 | GILEAD SCIENCES INC | Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors |
Jul, 2020
(2 years ago) | |
| EP1663240B1 | GILEAD SCIENCES INC | Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors |
Jul, 2020
(2 years ago) | |
| EP1632232A1 | GILEAD SCIENCES INC | Salt Of 4[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile |
Feb, 2022
(7 months ago) | |
| EP1632232B1 | GILEAD SCIENCES INC | Salt Of 4[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile |
Feb, 2022
(7 months ago) | |
| EP3808743B1 | GILEAD SCIENCES INC | Hiv Replication Inhibiting Pyrimidines |
Aug, 2022
(a month ago) | |
| EP2298761B1 | GILEAD SCIENCES INC | Hiv Inhibiting Pyrimidines Derivatives |
Aug, 2022
(a month ago) | |
| EP3808743A1 | GILEAD SCIENCES INC | Hiv Replication Inhibiting Pyrimidines |
Aug, 2022
(a month ago) | |
| EP2298761A1 | GILEAD SCIENCES INC | Hiv Inhibiting Pyrimidines Derivatives |
Aug, 2022
(a month ago) | |
| EP1789139A1 | GILEAD SCIENCES INC | Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile |
Sep, 2025
(2 years from now) | |
| EP1789139B1 | GILEAD SCIENCES INC | Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile |
Sep, 2025
(2 years from now) | |
| EP1419152B1 | GILEAD SCIENCES INC | Hiv Inhibiting Pyrimidines Derivatives |
Nov, 2026
(4 years from now) | |
| EP1419152A1 | GILEAD SCIENCES INC | Hiv Inhibiting Pyrimidines Derivatives |
Nov, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9744181 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 3 months from now) | |
| US8592397 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 3 months from now) | |
| US9457036 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 3 months from now) | |
| US8716264 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 3 months from now) | |
| US8841310 | GILEAD SCIENCES INC | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
Dec, 2025
(3 years from now) | |
| US10857102 | GILEAD SCIENCES INC | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
Jan, 2033
(10 years from now) | |
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 200MG;EQ 25MG BASE;300MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.